CeNeRx BioPharma TriRima shows good safety profile in study
CeNeRx said that these positive results further confirm the good safety profile demonstrated by TriRima in Phase I studies and set the stage for a Phase II clinical
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.
OncoMed’s lead candidate, OMP-21M18, is currently in Phase Ib clinical trials. OncoMed’s pipeline also includes several preclinical product candidates targeting multiple validated cancer stem cell pathways. OncoMed Pharma